Changes in metabolic parameters in psoriatic patients treated with secukinumab

BACKGROUND: Psoriasis is associated with cardiovascular disease and metabolic syndrome but the effects of interleukin (IL)-17A inhibitor treatment on metabolic parameters are unknown. This study aimed to determine the effects of secukinumab on metabolic parameters based on the disease activity and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hsuan Ning, Huang, Yu Huei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412909/
https://www.ncbi.nlm.nih.gov/pubmed/32821362
http://dx.doi.org/10.1177/2040622320944777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412909/
https://www.ncbi.nlm.nih.gov/pubmed/32821362
http://dx.doi.org/10.1177/2040622320944777

Ejemplares similares